

Synthesis of Substituted Cyclopentenenes from the Baylis-Hillman Adducts via Ring-Closing Metathesis Reaction

Ka Young Lee, Jeong Eun Na, Jin Yong Lee,[†] and Jae Nyoung Kim*

Department of Chemistry and Institute of Basic Science, Chonnam National University, Kwangju 500-757, Korea

[†]Institute for Condensed Matter Theory and Department of Chemistry, Chonnam National University, Kwangju 500-757, Korea

Received May 27, 2004

Key Words : Cyclopentenenes, Baylis-Hillman adducts, Ring-closing metathesis, Diethyl allylmalonate


Recently, we reported the synthesis of 2,5-dihydrofuran and 2,5-dihydropyrrole systems by using the well-known ring-closing metathesis (RCM) reaction from the slightly modified Baylis-Hillman adducts.¹ As a continuing effort we intended to synthesize the cyclopentene skeleton as shown in Scheme 1. Cyclopentene ring is a carbon analog of 2,5-dihydrofuran and 2,5-dihydropyrrole systems and we thought we could construct the cyclopentene ring by using the similar strategy, namely the combination of Baylis-Hillman chemistry and RCM reaction.

Substituted cyclopentenenes have been synthesized in a variety of ways²⁻⁴ including the ring-closing metathesis (RCM) reaction^{2,4} and have been used as useful synthetic intermediates and act as an important backbone of some


biologically important compounds.⁴

In order to introduce the required allyl moiety at the secondary position of the Baylis-Hillman adducts we used the well-known consecutive $S_N2'-S_N2'$ strategy involving DABCO salt of the bromide of the Baylis-Hillman adduct **1**, which was studied extensively by us and other groups.^{1,5} The reaction of dimethyl allylmalonate and the in-situ generated DABCO salt of **1a** in CH₃CN gave the corresponding addition-elimination product **2a** in good yield (84%). When we used aqueous THF instead of acetonitrile,⁵ the introduction of dimethyl allylmalonate required longer reaction time and showed lower yield of product.

With the compound **2a** in our hands we examined the RCM reaction. Generally the ring-closing metathesis reaction



Scheme 1




Scheme 2

*Corresponding Author. Phone: +82-62-530-3381, e-mail: kimjn@chonnam.ac.kr

Table 1. Synthesis of diallyl malonates **2** and cyclopentenones **3**

Entry	Condition	2 (% Yield)	3 (% Yield)
1	rt, 48 h	2a (84)	3a (95)
2	rt, 36 h	2b (78)	3b (89)
3	30–40 °C, 48 h	2c (80)	3c (95)
4	30–40 °C, 44 h	2d (69)	3d (97)
5	30–40 °C, 36 h	2e (60)	3e (99)
6	30–40 °C, 72 h	2f (75) ^a	3f (90)
7	30–40 °C, 48 h	2g (59) ^a	3g (93)

^aThe corresponding acetate was used instead of the bromide **1**.

involving electron-deficient alkene moiety as in **2a–g** required the use of second-generation Grubbs catalyst.^{1,6} The reaction of **2a** under the ring-closing metathesis condition using the second-generation Grubbs catalyst (**A**, 5 mol%) afforded the cyclopentene derivative **3a** in excellent yield (95%). The representative results are summarized in Table 1. As shown, excellent yields of desired RCM products were obtained irrespective of the substituents, ester, acetyl and nitrile.

As a useful transformation, we examined the catalytic hydrogenation reaction of **3a** using Pd/C (Scheme 3). The reaction at room temperature (MeOH under H₂ balloon) produced quantitative yield of desired product **4a** in a highly diastereoselective manner. Due to the steric hindrance of the phenyl moiety, the hydrogenation occurred at the opposite face.⁷ Trimethyl 2-phenylcyclopentane-1,1,3-tricarboxylate (**4a**) can be used for the preparation of 2-phenyl-1,3-cyclopentanedicarboxylic acid⁸ via sequential hydrolysis and decarboxylation.⁹

Diastereoselective decarboxylation⁹ and intramolecular Friedel-Crafts acylation reactions with **3a–g** are under progress in order to prepare tricyclic compound, which could be used for further transformation.

Experimental Section

Typical procedure for the synthesis of 2a. A mixture of the bromide **1a** (255 mg, 1 mmol) and DABCO (135 mg, 1.2 mmol) in CH₃CN (3 mL) was stirred at room temperature for 30 min. To the reaction mixture K₂CO₃ (152 mg, 1.1 mmol) and dimethyl allylmalonate (189 mg, 1.1 mmol) were added and stirred at room temperature for 48 h. After the usual aqueous workup and column chromatographic purification process (hexanes/ether, 10 : 1), **2a** was obtained as an oil, 291 mg (84%). Other compounds were synthesized similarly and their spectroscopic data are as follows.

2a: IR (neat) 1728, 1631 cm⁻¹; ¹H NMR (CDCl₃) δ 2.63

(dd, *J* = 14.1 and 7.8 Hz, 1H), 2.88 (ddt, *J* = 14.1, 6.6, and 1.2 Hz, 1H), 3.59 (s, 3H), 3.62 (s, 3H), 3.66 (s, 3H), 4.79 (s, 1H), 4.99–5.02 (m, 1H), 5.06 (s, 1H), 5.60–5.75 (m, 1H), 6.31 (d, *J* = 0.9 Hz, 1H), 6.44 (s, 1H), 7.18–7.31 (m, 5H); ¹³C NMR (CDCl₃) δ 40.57, 49.89, 52.02, 52.04, 52.08, 62.42, 119.04, 126.80, 127.27, 127.93, 130.05, 132.95, 137.61, 140.00, 167.35, 170.16, 170.82.

2b: ¹H NMR (CDCl₃) δ 1.12 (t, *J* = 7.2 Hz, 3H), 1.14 (t, *J* = 7.2 Hz, 3H), 2.65 (dd, *J* = 14.1 and 7.8 Hz, 1H), 2.90 (ddt, *J* = 14.1, 6.6, and 1.2 Hz, 1H), 3.66 (s, 3H), 3.99–4.15 (m, 4H), 4.80 (s, 1H), 4.99–5.02 (m, 1H), 5.05–5.06 (m, 1H), 5.61–5.76 (m, 1H), 6.35 (d, *J* = 0.6 Hz, 1H), 6.45 (s, 1H), 7.19–7.33 (m, 5H); ¹³C NMR (CDCl₃) δ 13.73, 13.84, 40.50, 49.64, 52.07, 61.12, 61.15, 62.05, 118.94, 126.95, 127.14, 127.85, 130.19, 133.06, 137.75, 140.04, 167.43, 169.73, 170.39.

2c: ¹H NMR (CDCl₃) δ 1.05 (t, *J* = 7.2 Hz, 3H), 1.08 (t, *J* = 7.2 Hz, 3H), 1.11 (t, *J* = 7.2 Hz, 3H), 2.58 (dd, *J* = 13.8 and 7.5 Hz, 1H), 2.84 (ddt, *J* = 12.6, 6.6, and 1.2 Hz, 1H), 3.92–4.09 (m, 6H), 4.72 (s, 1H), 4.94–5.00 (m, 2H), 5.55–5.69 (m, 1H), 6.26 (s, 1H), 6.38 (s, 1H), 7.09–7.26 (m, 5H); ¹³C NMR (CDCl₃) δ 13.73, 13.85, 14.01, 40.56, 49.72, 60.90, 61.10, 61.14, 62.03, 118.90, 126.61, 127.10, 127.80, 130.25, 133.13, 137.84, 140.24, 166.92, 169.72, 170.40.

2d: ¹H NMR (CDCl₃) δ 1.26 (t, *J* = 7.2 Hz, 3H), 1.33 (t, *J* = 7.2 Hz, 3H), 2.34 (dd, *J* = 14.1 and 7.8 Hz, 1H), 2.57 (ddt, *J* = 14.1, 6.6, and 1.5 Hz, 1H), 4.14–4.30 (m, 3H), 4.32 (s, 1H), 4.40–4.51 (m, 1H), 4.85–4.93 (m, 1H), 4.99–5.04 (m, 1H), 5.59–5.73 (m, 1H), 5.97 (s, 1H), 6.01 (s, 1H), 7.24–7.38 (m, 5H); ¹³C NMR (CDCl₃) δ 13.70, 14.00, 39.36, 53.29, 60.84, 61.69, 61.81, 118.48, 119.36, 124.15, 128.23, 128.82, 129.59, 132.06, 134.44, 135.08, 169.68, 169.76.

2e: ¹H NMR (CDCl₃) δ 1.11 (t, *J* = 7.2 Hz, 3H), 1.14 (t, *J* = 7.2 Hz, 3H), 2.28 (s, 3H), 2.64 (dd, *J* = 14.1 and 7.5 Hz, 1H), 2.87 (ddt, *J* = 14.1, 6.9, and 1.2 Hz, 1H), 3.95–4.17 (m, 4H), 4.92 (s, 1H), 4.97–5.02 (m, 1H), 5.04 (s, 1H), 5.61–5.75 (m, 1H), 6.27 (s, 1H), 6.56 (s, 1H), 7.17–7.32 (m, 5H); ¹³C NMR (CDCl₃) δ 13.74, 13.87, 25.91, 40.50, 47.69, 61.07, 61.12, 62.01, 118.89, 126.65, 127.02, 127.87, 130.13, 133.12, 138.19, 148.63, 169.89, 170.45, 198.75.

2f: ¹H NMR (CDCl₃) δ 1.22 (t, *J* = 7.2 Hz, 6H), 2.58 (dt, *J* = 7.2 and 1.2 Hz, 2H), 2.95 (d, *J* = 0.9 Hz, 2H), 3.70 (s, 3H), 4.04–4.22 (m, 4H), 5.04–5.11 (m, 2H), 5.63–5.65 (m, 1H), 5.66–5.76 (m, 1H), 6.24 (d, *J* = 1.5 Hz, 1H); ¹³C NMR (CDCl₃) δ 13.95, 33.63, 37.11, 51.89, 57.54, 61.23, 119.12, 129.11, 132.47, 135.91, 167.38, 170.53.

2g: ¹H NMR (CDCl₃) δ 1.25 (t, *J* = 7.2 Hz, 6H), 1.29 (t, *J* = 7.2 Hz, 3H), 2.60 (dt, *J* = 7.2 and 1.2 Hz, 2H), 2.98 (d, *J* = 0.9 Hz, 2H), 4.09–4.22 (m, 6H), 5.06–5.13 (m, 2H), 5.64 (d, *J* = 1.5 Hz, 1H), 5.70–5.82 (m, 1H), 6.26 (d, *J* = 1.5 Hz, 1H); ¹³C NMR (CDCl₃) δ 13.97, 14.09, 33.54, 37.12, 57.67, 60.85, 61.23, 119.05, 128.75, 132.58, 136.24, 166.95, 170.55.

Typical procedure for the ring-closing metathesis reaction of 3a. To a stirred solution of **2a** (173 mg, 0.5 mmol) in CH₂Cl₂ (10 mL) was added second-generation Grubbs catalyst (**A**, 21 mg, 5 mol%) and heated to reflux for 3 h. After removal of solvent and column chromatographic purification process (hexanes/ether, 9 : 1), **3a** was obtained

as an oil, 151 mg (95%). Other compounds were synthesized similarly and their spectroscopic data are as follows.

3a: IR (neat) 1736, 1639 cm^{-1} ; ^1H NMR (CDCl_3) δ 2.97 (dd, $J = 19.2$ and 3.0 Hz, 1H), 3.15 (s, 3H), 3.59 (s, 3H), 3.67 (dt, $J = 19.2$ and 2.4 Hz, 1H), 3.76 (s, 3H), 5.04-5.06 (m, 1H), 6.87-6.90 (m, 1H), 7.10-7.28 (m, 5H); ^{13}C NMR (CDCl_3) δ 39.67, 51.42, 51.99, 53.03, 55.56, 65.37, 127.32, 127.97, 128.39, 137.18, 137.32, 140.41, 163.70, 168.79, 171.61; Mass (70 eV) m/z (rel. intensity) 59 (100), 115 (44), 139 (38), 199 (47), 226 (44), 258 (46), 186 (21), 318 (M^+ , 32).

3b: ^1H NMR (CDCl_3) δ 0.86 (t, $J = 7.2$ Hz, 3H), 1.25 (t, $J = 7.2$ Hz, 3H), 2.96 (dd, $J = 19.5$ and 3.0 Hz, 1H), 3.46-3.52 (m, 1H), 3.59 (s, 3H), 3.65-3.75 (m, 2H), 4.15-4.31 (m, 2H), 5.03-5.05 (m, 1H), 6.86-6.89 (m, 1H), 7.12-7.27 (m, 5H); ^{13}C NMR (CDCl_3) δ 13.43, 13.93, 39.88, 51.48, 55.43, 61.31, 61.89, 65.25, 127.34, 128.00, 128.65, 137.54, 137.63, 140.35, 163.83, 168.55, 171.25.

3c: ^1H NMR (CDCl_3) δ 0.77 (t, $J = 7.2$ Hz, 3H), 1.01 (t, $J = 7.2$ Hz, 3H), 1.17 (t, $J = 7.2$ Hz, 3H), 2.87 (dd, $J = 19.5$ and 3.0 Hz, 1H), 3.37-3.44 (m, 1H), 3.58-3.67 (m, 2H), 3.87-4.05 (m, 2H), 4.10-4.75 (m, 2H), 4.96-4.98 (m, 1H), 6.78-6.80 (m, 1H), 7.05-7.15 (m, 5H); ^{13}C NMR (CDCl_3) δ 13.28, 13.75, 13.79, 39.82, 55.44, 60.05, 61.13, 61.72, 65.07, 127.10, 127.79, 128.58, 137.78, 137.82, 139.81, 163.23, 168.46, 171.16.

3d: ^1H NMR (CDCl_3) δ 0.81 (t, $J = 7.2$ Hz, 3H), 1.26 (t, $J = 7.2$ Hz, 3H), 2.93-3.01 (m, 1H), 3.39-3.45 (m, 1H), 3.65-3.74 (m, 2H), 4.17-4.34 (m, 2H), 5.05 (s, 1H), 6.73-6.76 (m, 1H), 7.14-7.31 (m, 5H); ^{13}C NMR (CDCl_3) δ 13.35, 13.93, 40.73, 57.53, 61.69, 62.25, 64.54, 115.07, 117.00, 128.31, 128.45, 128.93, 135.23, 145.53, 168.06, 170.54.

3e: ^1H NMR (CDCl_3) δ 0.80 (t, $J = 7.2$ Hz, 3H), 1.18 (t, $J = 7.2$ Hz, 3H), 2.14 (s, 3H), 2.94 (dd, $J = 19.5$ and 3.0 Hz, 1H), 3.36-3.47 (m, 1H), 3.60-3.71 (m, 2H), 4.05-4.25 (m, 2H), 5.00 (s, 1H), 6.71-6.74 (m, 1H), 7.02-7.20 (m, 5H); ^{13}C NMR (CDCl_3) δ 13.44, 13.94, 27.11, 40.24, 55.13, 61.34, 61.89, 65.12, 127.31, 128.05, 128.61, 137.74, 139.86, 146.23, 168.63, 171.27, 194.47.

3f: ^1H NMR (CDCl_3) δ 1.19 (t, $J = 7.2$ Hz, 6H), 3.09-3.12 (m, 2H), 3.17-3.20 (m, 2H), 3.67 (s, 3H), 4.13 (q, $J = 7.2$ Hz, 4H), 6.55 (quintet, $J = 2.1$ Hz, 1H); ^{13}C NMR (CDCl_3) δ 13.92, 39.40, 41.01, 51.52, 58.67, 61.78, 133.41, 139.72, 164.41, 171.27.

3g: ^1H NMR (CDCl_3) δ 1.26 (t, $J = 7.2$ Hz, 6H), 1.29 (t, $J = 7.2$ Hz, 3H), 3.16-3.19 (m, 2H), 3.24-3.27 (m, 2H), 4.19 (q, $J = 7.2$ Hz, 2H), 4.21 (q, $J = 7.2$ Hz, 4H), 6.61 (quintet, $J = 2.4$ Hz, 1H); ^{13}C NMR (CDCl_3) δ 13.90, 14.13, 39.38, 40.97, 58.63, 60.33, 61.73, 133.74, 139.33, 163.96, 171.29.

Catalytic hydrogenation of 3a. A mixture of **3a** (200 mg, 0.63 mmol) and 10% Pd/C (28 mg) in methanol (3 mL) was stirred at room temperature for 20 h under H_2 atmosphere (using balloon). After removal of solvent and column chromatographic purification (hexanes/ether, 2 : 1) we obtained **4a** (201 mg, oil) quantitatively. ^1H NMR (CDCl_3) δ 1.86-2.01 (m, 1H), 2.21-2.37 (m, 2H), 2.69-2.80 (m, 1H), 3.16 (s, 3H), 3.28-3.38 (m, 1H), 3.58 (s, 3H), 3.74 (s, 3H), 4.36 (d, $J = 10.8$ Hz, 1H), 7.16-7.29 (m, 5H); ^{13}C NMR (CDCl_3) δ 28.89, 34.44, 49.62, 52.08, 52.19, 52.97, 54.12, 65.63,

127.47, 128.26, 128.81, 138.57, 171.05, 172.41, 174.43.

Acknowledgments. This work was supported by the grant (R05-2003-000-10042-0) from the Basic Research Program of the Korea Science & Engineering Foundation. Spectroscopic data was obtained from the Korea Basic Science Institute, Kwangju branch.

References and Notes

- Kim, J. M.; Lee, K. Y.; Lee, S.-K.; Kim, J. N. *Tetrahedron Lett.* **2004**, 45, 2805.
- For the synthesis of cyclopentene derivatives by ring-closing metathesis reaction, see: (a) Grela, K.; Kim, M. *Eur. J. Org. Chem.* **2003**, 963. (b) Evans, P. A.; Kennedy, L. J. *Tetrahedron Lett.* **2001**, 42, 7015. (c) Wakamatsu, H.; Blechert, S. *Angew. Chem. Int. Ed.* **2002**, 794. (d) Nugent, W. A.; Feldman, J.; Calabrese, J. C. *J. Am. Chem. Soc.* **1995**, 117, 8992. (e) Fu, G. C.; Nguyen, S. T.; Grubbs, R. H. *J. Am. Chem. Soc.* **1993**, 115, 9856. (f) Coates, G. W.; Grubbs, R. H. *J. Am. Chem. Soc.* **1996**, 118, 229. (g) Alexander, J. B.; La, D. S.; Cefalo, D. R.; Hoveyda, A. H.; Schrock, R. R. *J. Am. Chem. Soc.* **1998**, 120, 4041. (h) Furstner, A.; Thiel, O. R.; Ackermann, L.; Schanz, H.-J.; Nolan, S. P. *J. Org. Chem.* **2000**, 65, 2204. (i) Chao, W.; Weinreb, S. M. *Org. Lett.* **2003**, 5, 2505. (j) Yang, C.; Murray, W. V.; Wilson, L. J. *Tetrahedron Lett.* **2003**, 44, 1783.
- For the synthesis of cyclopentene ring by other methods, see: (a) Du, Y.; Lu, X.; Zhang, C. *Angew. Chem. Int. Ed.* **2003**, 42, 1035. (b) Zhu, G.; Chen, Z.; Jiang, Q.; Xiao, D.; Cao, P.; Zhang, X. *J. Am. Chem. Soc.* **1997**, 119, 3836. (c) Zhang, C.; Lu, X. *J. Org. Chem.* **1995**, 60, 2906. (d) Allan, R. D.; Duke, R. K.; Hambley, T. W.; Johnston, G. A. R.; Mewett, K. N.; Quickert, N.; Tran, H. W. *Aust. J. Chem.* **1996**, 49, 785. (e) Citterio, A.; Sebastiano, R.; Nicolini, M. *Tetrahedron* **1993**, 49, 7743. (f) Sakito, Y.; Suzukamo, G. *Chem. Lett.* **1986**, 621. (g) Stevens, H. C.; Rinehart, J. K.; Lavanish, J. M.; Trenta, G. M. *J. Org. Chem.* **1971**, 36, 2780.
- For the synthesis of biologically important compounds containing cyclopentene skeleton, see: (a) Thorstensson, F.; Kvarnstrom, I.; Musil, D.; Nilsson, I.; Samuelsson, B. *J. Med. Chem.* **2003**, 46, 1165. (b) Holt, D. J.; Barker, W. D.; Jenkins, P. R. *J. Org. Chem.* **2000**, 65, 482. (c) Fang, Z.; Hong, J. H. *Org. Lett.* **2004**, 6, 993. (d) Hale, K. J.; Domostoj, M. M.; Tocher, D. A.; Irving, E.; Scheinmann, F. *Org. Lett.* **2003**, 5, 2927. (e) Chavez, D. E.; Jacobsen, E. N. *Org. Lett.* **2003**, 5, 2563. (f) Seepersaud, M.; Al-Abed, Y. *Org. Lett.* **1999**, 1, 1463. (g) Gillaizeau, I.; Charamon, S.; Agrofoglio, L. A. *Tetrahedron Lett.* **2001**, 42, 8817. (h) Handa, S.; Earlam, G. J.; Geary, P. J.; Hawes, J. E.; Phillips, G. T.; Pryce, R. J.; Ryback, G.; Shears, J. H. *J. Chem. Soc., Perkin Trans. 1* **1994**, 1885.
- For the introduction of nucleophiles at the secondary position of Baylis-Hillman adducts by using the DABCO salt concept, see: (a) Kim, J. N.; Lee, H. J.; Lee, K. Y.; Gong, J. H. *Synlett* **2002**, 173. (b) Gong, J. H.; Kim, H. R.; Ryu, E. K.; Kim, J. N. *Bull. Korean Chem. Soc.* **2002**, 23, 789. (c) Kim, J. M.; Lee, K. Y.; Kim, J. N. *Bull. Korean Chem. Soc.* **2004**, 25, 328. (d) Chung, Y. M.; Gong, J. H.; Kim, T. H.; Kim, J. N. *Tetrahedron Lett.* **2001**, 42, 9023. (e) Im, Y. J.; Kim, J. M.; Mun, J. H.; Kim, J. N. *Bull. Korean Chem. Soc.* **2001**, 22, 349.
- Chatterjee, A. K.; Morgan, J. P.; Scholl, M.; Grubbs, R. H. *J. Am. Chem. Soc.* **2000**, 122, 3783 and further references cited in reference 1.
- (a) Callam, C. S.; Lowary, T. L. *J. Org. Chem.* **2001**, 66, 8961. (b) Camps, P.; Colet, G.; Vazquez, S. *ARKIVOC* **2003**(x), 16.
- (a) Wilt, J. W.; Malloy, T. P.; Mookerjee, P. K.; Sullivan, D. R. *J. Org. Chem.* **1974**, 39, 1327. (b) Wilt, J. W.; Malloy, T. P. *J. Am. Chem. Soc.* **1970**, 92, 4747. (c) Zimmerman, H. E.; Cutshall, T. W. *J. Am. Chem. Soc.* **1958**, 80, 2893.
- Lee, J. Y.; Kim, J.; Lee, K. Y.; Kim, J. N. *J. Phy. Chem. A* **2004**, 108, 5678.